{
    "clinical_study": {
        "@rank": "65461", 
        "arm_group": [
            {
                "arm_group_label": "Fosfomycin and Daptomycin", 
                "arm_group_type": "Experimental", 
                "description": "fosfomycin 2gr/6h + 10mg/kg/24h  iv during 14 or 28 days"
            }, 
            {
                "arm_group_label": "Daptomycin", 
                "arm_group_type": "Active Comparator", 
                "description": "daptomycin 10mg/kg/cada 24h iv during 14 or 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin\n      alone in the treatment of Methicillin resistant Staphylococcus aureus (MRSA) bacteremia."
        }, 
        "brief_title": "Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia", 
        "condition": "Staph Aureus Methicillin Resistant Bacteremia", 
        "condition_browse": {
            "mesh_term": "Bacteremia"
        }, 
        "detailed_description": {
            "textblock": "The mortality associated to MRSA bacteremia remains higher than 30% of episodes. Objective:\n      To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin\n      alone in the treatment of Methicillin resistant Staphylococcus aureus (MRSA) bacteremia.\n      Design: Randomized, open and multicenter study. Intervention: Patients with MRSA bacteremia\n      will be randomized (1:1) in Group 1: Daptomycin 10mg/Kg/24h intravenous (iv) and Group 2:\n      Daptomycin 10 mg/kg/24 iv and Fosfomycin and 2g/6h iv. The duration of treatment is 10-14\n      days for uncomplicated bacteremia and 28 days for complicated bacteremia. There will be a\n      clinical and microbiological evaluation at baseline, during treatment and at 6 weeks after\n      the end of therapy. Complicated bacteremia: a) persistent bacteremia at 96 h from the onset\n      of the antibiotic, b) presence of distant source c) infection of 4 days non-removable\n      device. Assuming 60% cure rate with daptomycin and difference in cure rates of 20% between\n      both groups, we estimated that 103 patients would need to be enrolled in each group. Main\n      objective: clinical and microbiological response at 6 weeks from stopping treatment.\n      Treatment success was defined as resolution of sepsis symptoms and clinical signs and\n      negative blood cultures. Therapeutic failure was defined as either of the following: a) Lack\n      of response at 72 h after initiation of treatment or later based on clinical assessment b)\n      persistent bacteremia, c) withdrawal of treatment due to adverse effects or clinical\n      judgment. Secondary objectives: evaluation in both groups of clinical and microbiological\n      response and mortality at the end of treatment, persistent bacteremia and recurrent\n      bacteremia, emergence of daptomycin or fosfomycin resistance and adverse effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with at least 1 positive blood culture to MRSA Staphylococcus aureus within\n             de first 72h from the recruitment.\n\n          -  Adult patients, equal or older than 18 years old\n\n          -  Signed informed consent\n\n          -  Mandatory use of contraceptive for fertile women during the study period and the next\n             6 months to finalization.\n\n        Exclusion Criteria:\n\n          -  Polymicrobial bacteremia\n\n          -  Pneumonia associated to the bacteremia\n\n          -  Severe clinical status with a survival expectancy inferior to 24 hours.\n\n          -  Allergy to daptomycin or Fosfomycin\n\n          -  Positive pregnant test at inclusion time\n\n          -  Clinical status required the addition of other antibiotic therapy with\n             microbiological activity against MRSA, and it's not possible to stop it.\n\n          -  Patient included in another clinical trial\n\n          -  History od eosinophilic pneumoniae"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "206", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898338", 
            "org_study_id": "BACSARM", 
            "secondary_id": "2013-000586-37"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Fosfomycin and Daptomycin", 
                    "Daptomycin"
                ], 
                "intervention_name": "Fosfomycin 2gr/6h iv", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fosfomycin and Daptomycin", 
                "intervention_name": "Daptomycin  10mg/kg/24h iv", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fosfomycin", 
                "Daptomycin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "MRSA", 
            "bacteremia", 
            "therapy"
        ], 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bacelona", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i Sant Pau"
                }, 
                "investigator": {
                    "last_name": "Joaquin Lopez-Contreras, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de Llobregat", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08907"
                    }, 
                    "name": "Hospital Universitari de Bellvitge"
                }, 
                "investigator": {
                    "last_name": "Miquel Pujol, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sabadell", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08208"
                    }, 
                    "name": "Hospital Parc Taul\u00ed"
                }, 
                "investigator": {
                    "last_name": "Oriol Gasch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terrassa", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08227"
                    }, 
                    "name": "Hospital de Terrassa"
                }, 
                "investigator": {
                    "last_name": "Helena Espejo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terrassa", 
                        "country": "Spain", 
                        "state": "Barcelona", 
                        "zip": "08221"
                    }, 
                    "name": "Hospital Universitari M\u00fatua de Terrassa"
                }, 
                "investigator": {
                    "last_name": "Esther Calbo, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barakaldo", 
                        "country": "Spain", 
                        "zip": "48903"
                    }, 
                    "name": "Hospital Universitario de Cruces"
                }, 
                "investigator": {
                    "last_name": "Miguel Montejo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08036"
                    }, 
                    "name": "Hospital Clinic"
                }, 
                "investigator": {
                    "last_name": "Alex Soriano, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08003"
                    }, 
                    "name": "Hospital del Mar- Parc de Salut Mar"
                }, 
                "investigator": {
                    "last_name": "Milagro Montero, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Vall d'Hebron"
                }, 
                "investigator": {
                    "last_name": "Carles Pigrau, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada", 
                        "country": "Spain", 
                        "zip": "18014"
                    }, 
                    "name": "Hospital Universitario Virgen de las Nieves"
                }, 
                "investigator": {
                    "last_name": "Juan Pasquau, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lleida", 
                        "country": "Spain", 
                        "zip": "25198"
                    }, 
                    "name": "Hospital Universitari Arnau de Vilanova"
                }, 
                "investigator": {
                    "last_name": "Fernando Barcenilla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Gregorio Mara\u00f1on"
                }, 
                "investigator": {
                    "last_name": "Belen Padilla, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Ramon y Cajal"
                }, 
                "investigator": {
                    "last_name": "Vicente Pintado, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital Universitario 12 de Octubre"
                }, 
                "investigator": {
                    "last_name": "Ana Garcia-Reyne, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "zip": "07120"
                    }, 
                    "name": "Complejo Asistencial Son Espases"
                }, 
                "investigator": {
                    "last_name": "Javier Murillas, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41071"
                    }, 
                    "name": "Hospital Virgen Macarena"
                }, 
                "investigator": {
                    "last_name": "Jes\u00fas Rodriguez-Ba\u00f1o, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarragona", 
                        "country": "Spain", 
                        "zip": "43007"
                    }, 
                    "name": "Hospital Universitari Joan XXIII"
                }, 
                "investigator": {
                    "last_name": "Graciano Garcia Pardo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitari i Polit\u00e8ncic La Fe"
                }, 
                "investigator": {
                    "last_name": "Miguel Salavert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients", 
        "overall_contact": {
            "email": "mpujol@bellvitgehospital.cat", 
            "last_name": "Miquel Pujol, MD, PhD", 
            "phone": "+34 93 260 73 83", 
            "phone_ext": "7383"
        }, 
        "overall_contact_backup": {
            "email": "evelyn.shaw@bellvitgehospital.cat", 
            "last_name": "Evelyn Shaw, MD", 
            "phone": "+34 93 260 73 83", 
            "phone_ext": "7383"
        }, 
        "overall_official": {
            "affiliation": "(Infectious Diseases Service) Hospital Universitari de Bellvitge", 
            "last_name": "Miquel Pujol, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Therapy response is considered if clinical and microbiological response is achieved at 6th week post therapy", 
            "measure": "Therapy response", 
            "safety_issue": "No", 
            "time_frame": "at 6th week post therapy (an average of 8 to 10 weeks from the beginnig of therapy)"
        }, 
        "reference": [
            {
                "PMID": "12491202", 
                "citation": "Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003 Jan 1;36(1):53-9. Epub 2002 Dec 13."
            }, 
            {
                "PMID": "14530782", 
                "citation": "Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003 Sep;82(5):333-9."
            }, 
            {
                "PMID": "16914701", 
                "citation": "Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653-65."
            }, 
            {
                "PMID": "18782781", 
                "citation": "Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008 Dec;62(6):1413-21. doi: 10.1093/jac/dkn372. Epub 2008 Sep 8."
            }, 
            {
                "PMID": "19254641", 
                "citation": "Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Mir\u00f3 JM, Cercenado E, Dom\u00ednguez Mde L, Soriano A, Rodr\u00edguez-Ba\u00f1o J, Vall\u00e9s J, Palomar M, Tornos P, Bouza E; Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. [Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica]. Enferm Infecc Microbiol Clin. 2009 Feb;27(2):105-15. doi: 10.1016/j.eimc.2008.09.003. Epub 2009 Feb 11. Review. Spanish."
            }, 
            {
                "PMID": "19915879", 
                "citation": "Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):127-42. doi: 10.1007/s10096-009-0833-2. Epub 2009 Nov 14. Review."
            }, 
            {
                "PMID": "20186407", 
                "citation": "Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol. 2010 Apr;66(4):359-68. doi: 10.1007/s00228-010-0794-5. Epub 2010 Feb 26."
            }, 
            {
                "PMID": "21217178", 
                "citation": "Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011 Feb 1;52(3):285-92. doi: 10.1093/cid/cir034."
            }, 
            {
                "PMID": "21549573", 
                "citation": "Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents. 2011 Sep;38(3):192-6. doi: 10.1016/j.ijantimicag.2011.03.006. Epub 2011 May 6. Review."
            }, 
            {
                "PMID": "21612672", 
                "citation": "Chen LY, Huang CH, Kuo SC, Hsiao CY, Lin ML, Wang FD, Fung CP. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect Dis. 2011 May 26;11:152. doi: 10.1186/1471-2334-11-152."
            }, 
            {
                "PMID": "22644033", 
                "citation": "Mir\u00f3 JM, Entenza JM, Del R\u00edo A, Velasco M, Casta\u00f1eda X, Garcia de la M\u00e0ria C, Giddey M, Armero Y, Peric\u00e0s JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A; Hospital Clinic Experimental Endocarditis Study Group. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. Epub 2012 May 29."
            }, 
            {
                "PMID": "21923436", 
                "citation": "Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011 Jun;31(6):527-36. doi: 10.1592/phco.31.6.527."
            }, 
            {
                "PMID": "21862935", 
                "citation": "Gasch O, Ayats J, Angeles Dominguez M, Tubau F, Li\u00f1ares J, Pe\u00f1a C, Grau I, Pallar\u00e9s R, Gudiol F, Ariza J, Pujol M. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore). 2011 Sep;90(5):319-27. doi: 10.1097/MD.0b013e31822f0b54."
            }, 
            {
                "PMID": "23331461", 
                "citation": "Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MA, Benito N, Rodriguez-Ba\u00f1o J, Espejo E, Pujol M; on behalf of REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2012 Nov 22. doi: 10.1111/1469-0691.12108. [Epub ahead of print]"
            }, 
            {
                "PMID": "23089756", 
                "citation": "Garrig\u00f3s C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Jan;57(1):606-10. doi: 10.1128/AAC.01570-12. Epub 2012 Oct 22."
            }, 
            {
                "PMID": "23379510", 
                "citation": "Lai CC, Sheng WH, Wang JT, Cheng A, Chuang YC, Chen YC, Chang SC. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013 Feb 4;13:66. doi: 10.1186/1471-2334-13-66."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898338"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spanish Network for Research in Infectious Diseases", 
            "investigator_full_name": "Miquel Pujol", 
            "investigator_title": "MD and PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mortality", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed an average of 8 to 10 weeks from the begining of therapy"
            }, 
            {
                "description": "whatever", 
                "measure": "Severe adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed an average of 8 to 10 weeks from the begining of therapy"
            }, 
            {
                "description": "Defined as a persistent positive blood culture at day 7 of therapy.", 
                "measure": "Number of persistent bacteremia", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed an average of 8 to 10 weeks from the begining of therapy"
            }, 
            {
                "description": "Defined as a positive blood culture to MRSA when a previous negative sample existed", 
                "measure": "Bacteremia recurrence", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed an average of 8 to 10 weeks from the begining of therapy"
            }, 
            {
                "description": "Therapy response is considered if clinical and microbiological response is achieved at the end of therapy.", 
                "measure": "Therapy response", 
                "safety_issue": "No", 
                "time_frame": "at the end of therapy (up to 4 weeks)"
            }
        ], 
        "source": "Spanish Network for Research in Infectious Diseases", 
        "sponsors": {
            "collaborator": {
                "agency": "Hospital Universitari de Bellvitge", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Miquel Pujol", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}